Erudio Healtherudio.com
Indication
Pancreatic cancer
6 HCP commentary reports on clinical trials in Pancreatic cancer. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| AMPLIFY-7P NCT05726864 · Elicio Therapeutics | KRAS/NRAS-mutated solid tumors | Phase 1/Phase 2 | 255 | 75 | Standard 51 from 10 confirmed clinicians | Nov 4, 2026 | Preview |
| RMC-6236-001 NCT05379985 · Revolution Medicines, Inc. | RAS-mutant advanced solid tumors | Phase 1/Phase 2 | 196 | 49 | Standard 47 from 19 confirmed clinicians | Nov 4, 2026 | Preview |
| RMC-9805-001 NCT06040541 · Revolution Medicines, Inc. | advanced KRAS G12D-mutant solid tumors | Phase 1 | 117 | 45 | Focused 28 from 10 confirmed clinicians | Nov 2, 2026 | Preview |
| MAPKeeper 301 NCT07562152 · Immuneering Corporation | first-line metastatic pancreatic ductal adenocarcinoma | Phase 3 | 138 | 37 | Focused 64 from 3 confirmed clinicians | Nov 1, 2026 | Preview |
| RMC-GI-102 NCT06445062 · Revolution Medicines, Inc. | metastatic colorectal cancer or pancreatic ductal adenocarcinoma | Phase 1/Phase 2 | 38 | 19 | Focused 13 from 7 confirmed clinicians | Oct 29, 2026 | Preview |
| DAWN-303 NCT07522073 · Incyte Corporation | previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma | Phase 3 | 58 | 15 | Focused 25 from 3 confirmed clinicians | Oct 29, 2026 | Preview |